Colorectal Neoplasms, Neoplasm Metastasis
Conditions
Brief summary
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as CPT-11, Camptosar), 5-fluorouracil (also known as 5FU), and leucovorin (also known as LV). Preclinical data from animal models suggest that the investigational drug may offer an effective means for preventing CPT-11/5FU/LV-induced diarrhea. It is also hypothesized that the investigational drug-mediated anti-angiogenesis could induce a favorable tumor response.
Interventions
DRUGCelecoxib
DRUGIrinotecan
DRUG5-fluorouracil
DRUGLeucovorin
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of colorectal cancer (either newly diagnosed or recurrent disease) with evidence of metastatic disease and present or past histological documentation of adenocarcinoma of the colon or rectum. * Tumor must be measureable. * Resolution of all acute toxic effects of any prior radiotherapy or surgical procedure. * ECOG performance status 0 or 1. Age \>= 18 years. * Required baseline laboratory. * Negative pregnancy test. * Willingness and ability to comply with the treatment plan.
Exclusion criteria
* Current enrollment in another clinical trial. * Prior adjuvant therapy for colorectal cancer \<= 6 months prior to randomization. * Prior systemic anticancer therapy or intra-arterial cytotoxic chemotherapy given as treatment for metastatic colorectal cancer. * Known allergy to CPT-11, 5-FU, LV, celecoxib, other COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), salicylates, or sulfonamides. * Chronic concomitant use of full-dose aspirin, other NSAIDs or other COX-2 inhibitors for a chronic nonmalignant condition. * A requirement for chronic concomitant use of low-dose (cardioprotective) aspirin. * Chronic oral steroid use for treatment of a non-malignant condition. * Known ulceration of the gastric or duodenal mucosa \<= 30 days prior to randomization. * Need for concomitant fluconazole or lithium. * Any known significant bleeding disorder. * Active inflammatory bowel disease or chronic diarrhea.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of asthenia (fatigue), by week. | — |
| Severity of all grades of diarrhea, overall and by cycle | — |
| Duration of diarrhea, by cycle | — |
| Diarrhea grade, by day, by cycle | — |
| Asthenia will be assessed with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale. | — |
| Duration of asthenia, by week, as measured by the FACIT-Fatigue scale | — |
| Type, frequency, severity, timing, and relatedness of all adverse events CPT-11/5-FU/LV treatment administration as characterized by median, mean, and range of doses given; dose modifications, omissions, and delays; and actual and relative dose intensity | — |
| Compliance with celecoxib use Incidence, quantity, and duration of loperamide use | — |
| Stool count, by day, by cycle | — |
| Serum tumor marker (carcinoembryonic antigen [CEA]) response rate (as characterized by a 50% reduction from baseline) | — |
| Time to tumor progression (TTP) | — |
| Time to treatment failure (TTF) | — |
| Survival Post-study anticancer treatment | — |
| Peak plasma levels and AUC 0-24 values for CPT-11 and its major metabolites, SN-38, SN-38 glucuronide (SN-38G), and aminopentane carboxylic acid (APC) | — |
| Inflammatory cytokines which may serve as biomarkers for cancer-related outcomes Beta-glucuronidase as a potential biomarker for tumor response | — |
| Health resource utilization (collected data to be evaluated separately from this protocol) | — |
| Tumor response rate (overall and confirmed)using the World Health Organization [WHO] Response Evaluation Criteria in Solid Tumors [RECIST 2000] | — |
Countries
United States
Outcome results
None listed